Idorsia’s Jean-Paul Clozel retires as CEO, plots next steps; CRISPR Therapeutics nabs CMO from Sanofi

→ Jean-Paul Clozel is ready to pass the torch at his Actelion follow-up Idorsia, but he doesn’t want to walk away from the company altogether.

Clozel will retire as CEO on June 13, and Idorsia has tapped his longtime lieutenant André Muller to replace him. The 69-year-old Clozel will now stand for election as chairman, while Mathieu Simon moves into the vice chairman post.

The changes on the board don’t stop there. Jörn Aldag, Felix Ehrat and Peter Kellogg are stepping down, and Idorsia has nominated ex-Galapagos president Bart Filius.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Telehealth Pathway for IBD Surgery Expanded Access to Care in Small Study

ORLANDO — Utilization of a “total telemedicine pathway” for inflammatory bowel disease (IBD) surgery saved a considerable amount of mileage and time for patients treated

December 21, 2024

FDA alters warning label for Carvykti CAR-T, although link to secondary cancers is unclear

The Food and Drug Administration issued a change to the warning label for Legend Biotech and Janssen’s myeloma CAR-T, Carvykti or cilta-cel, adding that some

December 22, 2023

How UnitedHealth harnesses its physician empire to squeeze profits out of patients

This is the first in a periodic series about how UnitedHealth Group wields its unrivaled physician empire to boost its profits and expand its influence.

July 25, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.